Sumitomo Pharma Co., Ltd. (USD) Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Pharma Co., Ltd. (USD) Active

6-8, Doshomachi 2-chome, Osaka, JP, 541-0045

Stock Price USD

Price Change

Last Dividend USD

DNPUF's stock peer is BHHKF (Craftport Cannabis Corp.)

DNPUF's stock peer is BHNGF (Bhang Inc.)

DNPUF's stock peer is CANSF (Willow Biosciences Inc.)

DNPUF's stock peer is CPIX (Cumberland Pharmaceuticals Inc.)

DNPUF's stock peer is CVGRF (City View Green Holdings Inc.)

DNPUF's stock peer is CXXIF (C21 Investments Inc.)

DNPUF's stock peer is GHSI (Guardion Health Sciences, Inc.)

DNPUF's stock peer is GNMLF (Genomma Lab Internacional, S.A.B. de C.V.)

DNPUF's stock peer is HYPMY (Hypera S.A.)

DNPUF's stock peer is INVVY (Indivior PLC)

DNPUF's stock peer is IZQVF (Indivior PLC)

DNPUF's stock peer is LFCR (Lifecore Biomedical, Inc.)

DNPUF's stock peer is ORGO (Organogenesis Holdings Inc.)

DNPUF's stock peer is ORXOF (Orexo AB (publ))

DNPUF's stock peer is PTPI (Petros Pharmaceuticals, Inc.)

DNPUF's stock peer is RAMMF (RAMM Pharma Corp.)

DNPUF's stock peer is RVVQF (RavenQuest BioMed Inc.)

DNPUF's stock peer is SPBBF (Speakeasy Cannabis Club Ltd.)

DNPUF's stock peer is TKNO (Alpha Teknova, Inc.)

DNPUF's stock peer is YOURF (YourWay Cannabis Brands Inc.)

Healthcare Drug Manufacturers - Specialty & Generic

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2023-03-31	2023-06-28	0.05	2.34 %	Semi-Annual
2022-09-30	2022-12-01	0.10	2.57 %	Semi-Annual
2022-03-31	2022-06-24	0.11	2.35 %	Semi-Annual
2021-09-30	2021-12-01	0.13	1.54 %	Semi-Annual
2021-03-31	2021-06-25	0.13	1.39 %	Semi-Annual
2020-09-30	2020-12-01	0.13	1.94 %	Semi-Annual
2020-03-31	2020-06-24	0.13	1.98 %	Semi-Annual
2019-09-30	2019-12-02	0.13	12.56 %	Semi-Annual
2019-03-31	2019-06-21	2.00	7.94 %	Semi-Annual
2018-09-30	2018-12-03	0.08	1.13 %	Semi-Annual
2018-03-31	2018-06-20	0.18	1.73 %	Semi-Annual
2017-09-30	2017-12-01	0.08	1.24 %	Semi-Annual
2017-03-31	2017-06-23	0.08	54.70 %	Semi-Annual
		9.00	47.29 %	Semi-Annual
		0.08	1.42 %	Semi-Annual
		0.07	1.45 %	Semi-Annual
		0.08	1.59 %	Semi-Annual
		0.08	1.32 %	Semi-Annual
		0.09	55.45 %	Semi-Annual
		9.00	139.64 %	Semi-Annual
		9.00	53.80 %	Semi-Annual
		9.00	84.51 %	Semi-Annual

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions